Evidence map›Paper›PMID 18094721›Full record

GuidelineLeukemia2008

Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.

A Palumbo, S V Rajkumar, M A Dimopoulos, P G Richardson, J San Miguel, B Barlogie, J Harousseau, J A Zonder, M Cavo, M Zangari and 25 more

4 registry-linked trialsAbstract readPractice GuidelineReview
PubMed Publisher
In one paragraph

Guideline in Leukemia, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 268 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
268citing papers in PubMed, 10 pooled it
32.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01686386 phase1 / phase2unknown statusnot on this mapstarted 2010, after this paper: background citation

A Phase I/II Study of Bendamustine, Lenalidomide and Low-dose Dexamethasone, (BdL) for the Treatment of Patients With Relapsed Myeloma.

TypeinterventionalSponsorGruppo Italiano Studio LinfomiRan2010 to 2013Enrolled60ConditionsMultiple MyelomaArmsBendamustine, Lenalidomide, Dexamethasone
NCT02066454 phase3completednot on this mapstarted 2014, after this paper: background citation

Evaluation of the Use of an Oral Direct Anti-Xa Anticoagulant, Apixaban, in Prevention of Venous Thromboembolic Disease in Patients Treated With IMiDs During Myeloma : a Pilot Study

TypeinterventionalSponsorUniversity Hospital, GrenobleRan2014 to 2016Enrolled108ConditionsMyeloma, Venous ThromboembolismArmsApixaban
NCT03428373 phase2 / phase3unknown statusnot on this mapstarted 2019, after this paper: background citation

Rivaroxaban for Improvement of Thromboembolism Outcomes in Patients With Multiple Myeloma on Lenalidomide-based Therapy: RithMM Trial

TypeinterventionalSponsorLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sRan2019 to 2024Enrolled57ConditionsMultiple Myeloma in Relapse, Multiple Myeloma Progression, Multiple Myeloma Stage II, Multiple Myeloma Stage IArmsRivaroxaban, ASA
NCT05849610 phase2active not recruitingnot on this mapstarted 2023, after this paper: background citation

An Open Label, Multicenter, Phase 2, Pilot Study, Evaluating Early Treatment With Bispecific T-cell Redirectors (Teclistamab and Talquetamab) in the Frontline Therapy of Newly Diagnosed High-risk Multiple Myeloma

TypeinterventionalSponsorPETHEMA FoundationRan2023 to 2029Enrolled30ConditionsHigh-Risk de Novo Multiple MyelomaArmsDaratumumab, Bortezomib, Lenalidomide, Teclistamab, Talquetamab
3 · Its place in the literature

Who cites it

268 citing papers in PubMed, 10 syntheses or guidelines pooled it, 835 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology.Journal of the National Comprehensive Cancer Network : JNCCN · 2015
    Guideline
  9. Guideline
  10. Pooled it
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Venous Thromboembolism in Autologous Blood or Marrow Transplantation Survivors: A Report from the Blood or Marrow Transplant Survivor Study.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2019
    Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

208 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors at 20 institutions in 12 countries.

A PalumboDivision of Hematology, University of Turin, Azienda Ospedaliera S. Giovanni Battista, Torino, Italy. appalumbo@yahoo.com
S V Rajkumar
M A Dimopoulos
P G Richardson
J San Miguel
B Barlogie
J Harousseau
J A Zonder
M Cavo
M Zangari
M Attal
A Belch
S Knop
D Joshua
O Sezer
H Ludwig
D Vesole
J Bladé
R Kyle
J Westin
D Weber
S Bringhen
R Niesvizky
A Waage
M von Lilienfeld-Toal
S Lonial
G J Morgan
R Z Orlowski
K Shimizu
K C Anderson
M Boccadoro
B G Durie
P Sonneveld
M A Hussein
International Myeloma Working Group
Azienda Ospedaliero Universitaria San Giovanni Battista · ITDana-Farber Cancer Institute · USUniversity of Arkansas for Medical Sciences · USCedars-Sinai Medical Center · USCharité - Universitätsmedizin Berlin · DECleveland Clinic · USComplejo Hospitalario de Salamanca · ESCornell University · USEmory University · USErasmus MC · NLHôpital Purpan · FRHôtel-Dieu de Paris · FRInstitute of Cancer Research · GBLund University · SEMayo Clinic · USMayo Clinic in Arizona · USNational and Kapodistrian University of Athens · GRRoyal Prince Alfred Hospital · AUSaint Vincent Health System · USSt James's University Hospital · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The incidence of venous thromboembolism (VTE) is more than 1 per thousand annually in the general population and increases further in cancer patients. The risk of VTE is higher in multiple myeloma (MM) patients who receive thalidomide or lenalidomide, especially in combination with dexamethasone or chemotherapy. Various VTE prophylaxis strategies, such as low-molecular-weight heparin (LMWH), warfarin or aspirin, have been investigated in small, uncontrolled clinical studies. This manuscript summarizes the available evidence and recommends a prophylaxis strategy according to a risk-assessment model. Individual risk factors for thrombosis associated with thalidomide/lenalidomide-based therapy include age, history of VTE, central venous catheter, comorbidities (infections, diabetes, cardiac disease), immobilization, surgery and inherited thrombophilia. Myeloma-related risk factors include diagnosis and hyperviscosity. VTE is very high in patients who receive high-dose dexamethasone, doxorubicin or multiagent chemotherapy in combination with thalidomide or lenalidomide, but not with bortezomib. The panel recommends aspirin for patients with < or = 1 risk factor for VTE. LMWH (equivalent to enoxaparin 40 mg per day) is recommended for those with two or more individual/myeloma-related risk factors. LMWH is also recommended for all patients receiving concurrent high-dose dexamethasone or doxorubicin. Full-dose warfarin targeting a therapeutic INR of 2-3 is an alternative to LMWH, although there are limited data in the literature with this strategy. In the absence of clear data from randomized studies as a foundation for recommendations, many of the following proposed strategies are the results of common sense or derive from the extrapolation of data from many studies not specifically designed to answer these questions. Further investigation is needed to define the best VTE prophylaxis.

Indexed as

Antineoplastic AgentsAspirinHeparin, Low-Molecular-WeightHumansInternational Normalized RatioLenalidomideMultiple MyelomaPremedicationRisk AssessmentRisk FactorsThalidomideThrombosisVenous ThromboembolismWarfarinAntineoplastic AgentsAspirinHeparin, Low-Molecular-WeightLenalidomideThalidomideWarfarin

Identifiers

PMID18094721
OpenAlexW2097331346

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.